Kornimate/medical-research-clean huggingface dataset:
moca test for the early detection of mild cognitive impairment during annual assessment of young adults with diabetes and in a control group without diabetes

Conditions: Diabetes Mellitus Type 1; Diabetes Mellitus Type 2; Mild Cognitive Impairment

Summary: t2d and cognitive impairment are two of the most common chronic condition found in persons 60 years and older. diabetes type 2 increases with age and studies suggest that the diabetes is one of the risk factor for cognitive impairment and dementia. although there is much recent research showing that diabetics at every age have more cognitive impairment and dementia than non-diabetics, relatively little attention has been paid to the implications of this complication in the management of t2d in terms of screening, prevention, education and treatment adherence. there are now guidelines for periodic evaluation of patients with diabetes as early detection of complications of the disease, but so far there are no similar assessment and monitoring of cognitive function. in this study the investigators examine cognitive function in young diabetic patients (from 20 to 55) using the moca test, that allows detection of mild cognitive impairment, and may be carried out during a visit, an annual advisory diabetes clinic.

1. patients on a routine visit to the diabetes clinic, who meet the inclusion criteria, will be recruited for the test. they will be given an explanation of the study and the questionnaire by the principal investigator. 2. sign a consent form. 3. performance and execution of moca test: * fingerstick blood glucose for pre-cognitive testing performed (to avoid testing any participant with a serum glucose \< 70 mg/dl); * in the presence of hypoglycemia, the participant should be given a snack and begin the test only after the glucose level rises. alternatively delay executing the test 4. details from the patient's file are registered, such as: duration of the disease, family history, presence of macro and micro vascular complications, lifestyle, years of education, and the results of relevant laboratory accuracy. 5. for each patient a medical file is opened containing the initials and serial number of his research. all results are then encoded and analyzed anonymously

Eligibility criteria:
inclusion criteria: * type 1 and 2 diabetes meilitus * 20 to 55 years old * up to 15 years of diabetes disease duration * fluent speech and read hebrew's language only exclusion criteria: * not meeting the inclusion criteria * psychiatric disease * dementia * chronic use of alcohol or illegal drugs * use of medication that can alter the attention or cognition of the participant * active cardiovascular disease in the previous six months before the investigation * oncology disease in the previous six months before the investigation
evaluating the effect of perioperative caloric restriction program on perioperative outcomes in patients with obesity and endometrial cancer

Conditions: Obese; Endometrial Cancer

Summary: 80% of endometrial cancer patients are overweight or obese. preclinical and clinical data have shown that caloric restriction (cr) protects against organ injury and decreases perioperative morbidity. this is a feasibility trial to evaluate the effect of a 6 week perioperative cr on surgical and patient-reported outcomes in 20 obese newly diagnosed endometrial cancer patients. the intervention will provide individualized cr program, meal replacement products and nutritional counselling sessions.


Eligibility criteria:
inclusion criteria: * newly diagnosed with endometrial cancer * bmi30 kg/m2 * 18 year of age or older * scheduled for definitive surgical intervention (hysterectomy, bilateral salpingoopherectomy with or without lymphadenectomy) in the following 2-3 weeks as part of the standard of care * have ecog performance status of 0-1 * have a life expectancy of at least 1 year exclusion criteria: * inability to communicate in english * bmi30 kg/m2 * age18 * have any uncontrolled serious medical or psychiatric conditions that would affect their ability to participate in an intervention study, (e.g., severe/uncontrolled diabetes mellitus, severe cardiac and/or pulmonary disease and/or depression) * diagnosed with any other invasive malignancy currently, in the last five years or expected to undergo active treatment with either cytotoxic chemotherapy or radiation during the 6 week caloric restriction period

Keywords: newly diagnosed patients
e. max laminate veneers with and without using galla chinnesis as natural cross linking and remineralizing agent

Conditions: Amelogenesis Imperfecta

Summary: in teeth requiring laminate veneers with amelogenesis imperfecta will application of galla chinensis before bonding of laminate veneers with adhesive resin cement provide better survival rate than conventional bonding method

one year clinical evaluation of laminate veneers with amelogenesis imperfecta will application of galla chinensis before bonding of laminate veneers with adhesive resin cement provide better survival rate than conventional bonding method

Eligibility criteria:
inclusion criteria: all subjects are required to be: * from 18-60 years old, and able to read and sign the informed consent document. * physically and psychologically able to tolerate conventional restorative procedures * have no active periodontal or pulpal diseases, have teeth with good restorations * patients with teeth problems indicated for laminate veneer (e.g. discoloration, fracture not involve more than 50% enamel loss, mild malposition, ....) * willing to return for follow-up examinations and evaluation exclusion criteria: * patients in the growth stage with partially erupted teeth * patient with fractured teeth of more than 50% enamel loss * patients with poor oral hygiene and motivation * pregnant women * psychiatric problems or unrealistic expectations * lack of opposite occluding dentition in the area intended for restoration
evaluation of the effects of using cooling pillowcases, on the symptoms of hot flushes, sleep and life quality

Conditions: Breast Cancer

Summary: this study was planned to evaluate the effect of education on the management of side effects and the use of cooling pillowcase on hot flush complaints, sleep and quality of life in women with breast cancer receiving hormone therapy.

it is planned to apply pre-test evaluations in the 1st week and post-test evaluations in the 9th week to the intervention (training) group consisting of women with breast cancer who agree to participate in the study. a total of 3 follow-ups will be performed on the patients in the intervention (education) group in weeks 3 and 7 by telephone interview method and in week 5 by face-to-face interview method using the patient follow-up form. in addition, in order to evaluate the effectiveness of the education given to the patients in the intervention (education) group, the practices for coping with the side effects of hormone therapy form will be completed in the 5th and 9th weeks. the control group consisting of women with breast cancer who agreed to participate in the study will be administered pre-test evaluations at week 1 and post-test evaluations at week 9. the patients in the control group will not be subjected to any intervention by the researcher, their routine treatment and care will continue, and they will be followed up only once in the 5th week by phone call.

Eligibility criteria:
inclusion criteria: * 18 years of age or older, * estrogen and progesterone receptor positive, stage 1, 2, 3 or 4 primary breast cancer, * receiving hormone therapy (goserelin acetate subcutaneously every 4 weeks), * pre/perimenopausal period, * no sensory and emotional barriers to communication, * understands turkish, can read and write, * patients who voluntarily agreed to participate in the study. exclusion criteria: * receiving treatment for anxiety and/or depression, * receiving gabapentin treatment for neuropathic pain, * active viral or bacterial infection, * patients with a history of sleep disorders diagnosed before hormone therapy.

Keywords: hormone therapy breast cancer cooling pillowcase hot flashes quality of life
impact of dolutegravir+lamivudine simplification on hiv-1 reservoirs

Conditions: HIV Infections

Summary: for a few years, there has been a keen interest of clinicians and patients for "lighter" antiretroviral strategies based on two- or even single drug regimens rather than the canonical triple therapy, both as initial and maintenance therapy, despite the possibility that ongoing viral replication may occur in some patients under triple-therapy. we will therefore propose such simplification strategy (dtg/3tc) while maintaining triple-therapy (dtg/abc/3tc) in a control group and will perform an in depth analysis of the replication-competent reservoir in blood and in tissues as well as measurements of residual viremia and immune chronic activation/inflammation.


Eligibility criteria:
inclusion criteria: * hiv-infected adults receiving cart for at least 2 years * dtg/3tc/abc as cart regimen in the previous 6 months. * cd4 counts higher than 200 cells per μl and virological suppression for at least 2 years (plasma hiv rna \<20 copies per ml) exclusion criteria: * hepatitis c or b co-infection * unstable liver disease * renal impairment (estimated glomerular filtration rate \<50 ml per min), * gastrointestinal disorders that would affect the absorption of study treatment * current use of drugs with significant interactions with dolutegravir * current use of drugs with an impact on inflammation such as steroids. * hospitalization for acute illness within the previous 8 weeks * pregnancy or breastfeeding. * known resistance to dtg or 3tc * active tuberculosis * anal or rectal lesions impeding rectal biopsies * decreased platelets count or coagulation disorder.
effect of acupoint stimulation on postoperative delirium and electroencephalogram

Conditions: Anesthesia; Postoperative Delirium; Electroencephalogram

Summary: transcutaneous electrical acupoint stimulation (teas) was reported to benefit the patients undergoing surgeries by reducing anesthetics consumption and decreasing anesthesia related adverse effects. electroencephalogram (eeg) and eeg-related indicators are important indicators reflecting the conscious state of the brain, and different anesthetic drugs and anesthesia depths cause different eeg characteristic changes. the mechanism by which teas improves postoperative delirium (pod) is not clear, and whether changes in eeg characteristic parameters is involved needs to be further explored. therefore, this study aims to observe the effect of teas at neiguan and shenmen acupoint on pod in elderly patients undergoing abdominal surgery, and to explore the eeg related mechanism underlying teas improving pod.


Eligibility criteria:
inclusion criteria: 1. aged 65 years or older 2. american society of anesthesiologists (asa) classification≤ grade iii 3. patients scheduled for elective abdominal surgery under general anesthesia 4. informed consent exclusion criteria: 1. patients with severe central nervous system injury or severe cerebrovascular disease 2. patients with cognitive dysfunction assessed by confusion assessment method before surgery 3. patients unable to cooperate with studies, such as psychiatric disorders or difficulty in communication 4. patients with severe hepatic and renal insufficiency 5. patients with severe respiratory diseases 6. patients with contraindication for transcutaneous electrical stimulation, such as implanted electrophysiological devices, skin infection and damage at acupuncture points 7. anticipated duration of anesthesia shorter than 2 hours or postoperative hospital stay shorter than 3 days

Keywords: transcutaneous electrical acupoint stimulation postoperative delirium electroencephalogram
standard drug therapy vs. implanted defibrillator for primary prevention of sudden cardiac death

Conditions: Coronary Heart Disease; Congestive Heart Failure; Ventricular Dysfunction; Low Cardiac Output; Sudden Cardiac Death

Summary: recent acc/aha/esc guidelines recommend prophylactic icd implantation in most patients with coronary heart disease and lvef \< 40%. current canadian guidelines recommend icds for primary prophylaxis in cad patients with lvef \< 30% (class i recommendation). there are very sparse data to recommend icd implantation in patients with ef between 30 and 40 %. this study will randomize patients with chd and an ef between 30 and 40% to icd therapy vs. no icd therapy. the primary outcome is mortality and the study is powered as a non-inferiority trial to test the hypothesis that mortality in patients with no icd is not more than 1% greater (absolute yearly increase) than patients receiving an icd.


Eligibility criteria:
inclusion criteria: * documented chronic coronary heart disease (prior mi and/or angiographically documented cad), \> 40 days post the most recent mi; * lvef \< 40% (by muga) and nyha functional class ii or iii at time of assessment or lvef ≤ 35 % (by muga) and nyha functional class i, ii or iii at time of assessment * judged to have a reasonable expectation of survival with a good functional status for more than 1 year, as well as receiving optimum, guideline recommended therapy for coronary artery disease and heart failure (or demonstrated intolerance or contraindications to such therapy). * age ≥ 18 years; no upper age limitation. exclusion criteria: * prior cardiac arrest, sustained vt or vf, or unexplained syncope. * attempted vt / vf induction at electrophysiological study. * need for a cardiac resynchronization therapy (crt) device. * enrollment in another interventional trial.

Keywords: implantable cardioverter defibrillator ejection fraction qrs duration
load control in eccentric exercises in volleyball players

Conditions: Patellar Abnormality

Summary: introduction. vertical jump is the main movement in volleyball, and the main etiological factor of patellar tendinopathy. the eccentric exercise has been proved as the most effective intervention in improving this factor. aim. annalise the effectiveness of the load control during the eccentric exercise to increase the cross-sectional area as well as the increase of the pain threshold of the patellar tendon, and the gain of the quadriceps maximum strength, in volleyball older players. study design. randomized clinical study, simple blind, multicentric and with a follow-up period. methods. 40 volleyball players will be recruited, who will be randomized to the two groups: experimental (control of the load based on the rm during the eccentric exercise of quadriceps) and control (without load control). there will be an intervention of 4 weeks with 2 weekly seasons of 10 minutes each. the dependent variables will be: cross-sectional area (ultrasound evaluation), pain threshold in the patellar tendon (analog or digital algometer) and the maximum strength of the quadriceps (linear encoder or estimating the rm). in case of normality of the distribution of the sample, parametric tests will be used: student t-test of related samples (difference between evaluations in each rump) and repeated measures anova (intra- and intergroup effect). expected results. to observe an increase in the cross-sectional area, pain-threshold of patellar tendon and quadriceps maximum strength.


Eligibility criteria:
inclusion criteria: * volleyball players * federated that at the time of the study compete in clubs of the community of madrid * over 18 years old. exclusion criteria: * present a medical diagnosis of injury or illness * have suffered a knee injury in the 6 months prior to the study * doing some pharmacological or physiotherapy treatment external to the study * not signed the informed consent document.

Keywords: eccentric load control volleyball physiotherapy patellar tendon randomized clinical trial
feasibility of a trial evaluating the effectiveness of occupational therapy in parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this study is to determine the feasibility of a rct evaluating the effectiveness of occupational therapy in parkinson's disease.

parkinson's disease is a complex disabling condition progressively affecting activities and participation of patients. occupational therapy aims to optimise functional performance and engagement in meaningful roles and activities. the lack of scientific evidence for the effectiveness of occupational therapy (ot) in parkinson's disease (pd) highlights the urgent need for high quality intervention studies. the recently developed dutch clinical practice guideline for ot in pd offers a good basis for conducting an intervention study. this proposed pilot study is an important step towards setting up a large scale rct to evaluate the effectiveness of ot in improving daily functioning of patients with pd and reducing caregivers' burden.

Eligibility criteria:
inclusion criteria patients: * idiopathic parkinson's disease according to uk brain bank criteria * home dwelling * indication for occupational therapy (according to criteria in the evidence based guideline) inclusion criteria caregivers: * available to provide informal support minimal two times a week to a patient who participates in the study. exclusion criteria patients: * not capable of completing the self assessment forms (i.e. due to language or severe cognitive problems) * comorbidity with symptoms that interfere with actively taking part in the intervention (e.g psychosis, severe heart condition). or limitations in activities are dominated by the co morbid condition rather than by parkinson's disease. * current participation in other allied health research (impact, parkfit, ergodim) * having received occupational therapy intervention in the last 12 months

Keywords: occupational therapy parkinson's disease feasibility effectiveness rct activities of daily living participation caregiver's burden
methylprednisolone in the treatment of patients with signs of severe acute respiratory syndrome in covid-19

Conditions: SARS-CoV Infection; Severe Acute Respiratory Syndrome (SARS) Pneumonia

Summary: this is a double-blind, randomized, placebo-controlled, phase iib clinical trial to assess the efficacy of injectable methylprednisolone sodium succinate (mp) in patients with severe acute respiratory syndrome (sars) in covid-19 infection. a total of 416 individuals of both sexes, aged over 18 years old, with symptoms suggestive or confirmed diagnosis of severe acute respiratory syndrome (sars), hospitalized at the hospital and pronto-socorro delphina rinaldi abdel aziz (hpsdraa), with clinical and radiological findings suggestive of sars-cov2 infection, will be randomized at a 1:1 ration to receive either mp (0.5mg/kg of weight, twice daily, for 5 days) or placebo (saline solution, twice daily, for 5 days).


Eligibility criteria:
inclusion criteria: 1. suspected cases of covid-19, from clinical and radiological data, during the pandemic; 2. adult aged 18 years or older, at the time of inclusion (children under 18 will not be included due to the recognized lower lethality in previous published studies, and the difficulty of consent in the context of an emergency in public health); 3. spo2 ≤ 94% in room air or in use supplementary oxygen or under invasive mechanical ventilation exclusion criteria: 1. history of hypersensitivity to mps; 2. people living with hiv and aids; 3. chronic use of corticosteroids or immunosuppressive agents; 4. pregnancy or breastfeeding; 5. decompensated cirrhosis; 6. chronic renal failure.

Keywords: sars-cov-2 covid-19 corticosteroid severe acute respiratory syndrome (sars) pneumonia coronavirus methylprednisolone
self-scored cardiovascular disease risk appraisal

Conditions: Cardiovascular Diseases; Heart Diseases; Coronary Heart Disease Risk Reduction

Summary: to develop and test a self-scored cardiovascular disease health risk appraisal.

background: health risk appraisals (hra) are being used increasingly by health centers and worksites to inform people of their personal mortality and morbidity risks. however, recent research suggests that many hras have limited reliability and validity with respect to coronary heart disease, the leading cause of death in this country. self-scored hras appear to be considerably less accurate in predicting chd risk than computerized instruments, chiefly because people do not always know the physiologic values required by these instruments and because they frequently make errors computing their scores. design narrative: during phase i, a new appraisal named cardiorisk was developed. the phase i prototype version contained eight major self-reported risk factors. cardiorisk predicted the risk of developing cardiovascular disease (cvd) in a 12-year period using an equation based on recent accelerated failure time models from the framingham heart study. the purpose of phase ii was to thoroughly test and refine the prototype instrument. the phase ii analyses were designed to assess the psychometric properties of cardiorisk, to evaluate its utility as judged by patients, and to determine whether the instrument changed perceptions of personal cvd risk. these results were compared to data for other appraisals to determine whether cardiorisk outperformed comparable products. in the proposed commercial application, cardiorisk would be distributed by health promotion organizations to increase awareness of the risk factors for cardiovascular disease. estimates from the american heart association put the demand for these products at 180,000 hras per year. the potential market for this product includes worksites, community health centers, managed health care organizations, public health departments, and clinics. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
dose-finding study of m516102 in the treatment of pruritus associated with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this study is to investigate the efficacy and safety of m516102 and to evaluate the dose response relationship of m516102 and placebo, in the treatment of pruritus associated with atopic dermatitis.


Eligibility criteria:
inclusion criteria: 1. male or female patients (aged 18-65 years) with a diagnosis of ad. 2. female patients of child bearing potential must be using a medically acceptable form of contraception. 3. patients who are able and willing to give signed informed consent. 4. patients who have pruritus exceed the reference range. exclusion criteria: 1. patients who have a history of allergy to hydrocortisone. 2. patients who have a history of relevant drug hypersensitivity. 3. patients who have a history of contact dermatitis induced by a topical steroid. 4. patients who are taking, and who are unwilling not to take, any medications or therapy prohibited by the protocol for the complete duration of the study. 5. patients who have a history or presence of any cancer. 6. patients who have any renal or liver insufficiency, or clinically significant cardiac, renal or hepatic disease. 7. patients who, in the opinion of the investigator, are not deemed eligible as determined by medical history, physical examination or clinical laboratory safety tests. 8. patients who have pruritus associated with conditions other than ad. 9. patients who have pruritus only on the face and head. 10. patients who, in the opinion of the investigator, have clinically relevant history or presence of any disease, or surgical history other than ad which is likely to affect the conduct of the study. 11. patients who have used m5161(active ingredient of m516102). 12. patients who cannot communicate reliably with the investigator. 13. patients who are pregnant or lactating. 14. patients who have used any imp and/or participated in any clinical trial within 3 months.